CD19 and neoplasm: Following CD19 CAR T therapy, initial response rates for relapse or refractory pediatric B-ALL are 80–90%, but ultimately approximately 50% of patients will relapse because of either loss of CD19 expression on the tumor cells [5] or a lack of CAR T cell persistence [6,7].